Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Feb 2;9(2):148-155.
doi: 10.1093/ehjcvp/pvac056.

Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

Seth S Martin  1 , Marc Ditmarsch  2 , Mark Simmons  3 , Nicholas Alp  3 , Traci Turner  3 , Michael H Davidson  2   4 , John J P Kastelein  2   5
Affiliations
Randomized Controlled Trial

Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

Seth S Martin et al. Eur Heart J Cardiovasc Pharmacother. .

Abstract

Aims: Low-density lipoprotein (LDL-C) lowering is imperative in cardiovascular disease prevention. We aimed to compare accuracy of three clinically-implemented LDL-C equations in a clinical trial of cholesterol ester transfer protein (CETP) inhibition.

Methods and results: Men and women aged 18-75 years with dyslipidaemia were recruited from 17 sites in the Netherlands and Denmark. Patients were randomly assigned to one of nine groups using various combinations of the CETP inhibitor TA-8995 (obicetrapib), statin therapy, and placebo. In pooled measurements over 12 weeks, we calculated LDL-C by the Friedewald, Martin/Hopkins, and Sampson equations, and compared values with preparative ultracentrifugation (PUC) LDL-C overall and with a special interest in the low LDL-C/high triglycerides subgroup. There were 242 patients contributing 921 observations. Overall median LDL-C differences between estimates and PUC were small: Friedewald, 0.00 (25th, 75th: -0.10, 0.08) mmol/L [0 (-4, 3) mg/dL]; Martin/Hopkins, 0.02 (-0.08, 0.10) mmol/L [1 (-3, 4) mg/dL]; and Sampson, 0.05 (-0.03, 0.15) mmol/L [2 (-1, 6) mg/dL]. In the subgroup with estimated LDL-C <1.8 mmol/L (<70 mg/dL) and triglycerides 1.7-4.5 mmol/L (150-399 mg/dL), the Friedewald equation underestimated LDL-C with a median difference versus PUC of -0.25 (-0.33, -0.10) mmol/L [-10 (-13, -4) mg/dL], whereas the median difference by Martin/Hopkins was 0.00 (-0.08, 0.10) mmol/L [0 (-3, 4) mg/dL] and by Sampson was -0.06 (-0.13, 0.00) mmol/L [-2 (-5, 0) mg/dL]. In this subgroup, the proportion of LDL-C observations <1.8 mmol/L (<70 mg/dL) that were correctly classified compared with PUC was 71.4% by Friedewald vs. 100.0% by Martin/Hopkins and 93.1% by Sampson.

Conclusion: In European patients with dyslipidaemia receiving a CETP inhibitor, we found improved LDL-C accuracy using contemporary equations vs. the Friedewald equation, and the greatest accuracy was observed with the Martin/Hopkins equation.

Registration: ClinicalTrials.gov, NCT01970215.

Keywords: Accuracy; Cholesterol ester transfer protein inhibition; Friedewald equation; Low-density lipoprotein cholesterol; Martin/Hopkins equation; Sampson equation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TULIP trial profile and low-density lipoprotein cholesterol accuracy analysis population. The figure depicts the flow of patients through the TULIP trial and the analysis population, which includes all available low-density lipoprotein cholesterol observations. Observations are defined as blood samples with available standard lipid profile data to estimate low-density lipoprotein cholesterol and direct measurement of low-density lipoprotein cholesterol by preparative ultracentrifugation. TULIP, TA-8995 in Patients with Mild Dyslipidaemia; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.
Figure 2
Figure 2
Waterfall plot of differences between low-density lipoprotein cholesterol estimates and preparative ultracentrifugation. Differences are shown in mmol/L overall for each low-density lipoprotein cholesterol equation and in subgroups with estimated low-density lipoprotein cholesterol  <1.8 mmol/L (<70 mg/dL) and triglyceride levels 1.7–4.5 mmol/L (150–399 mg/dL). Difference in low-density lipoprotein cholesterol vs. preparative ultracentrifugation = (low-density lipoprotein cholesterol by specified equation method)—(low-density lipoprotein cholesterol by preparative ultracentrifugation). PUC, preparative ultracentrifugation; LDL-C, low-density lipoprotein cholesterol.
Figure 3
Figure 3
Proportion of low-density lipoprotein cholesterol levels classified by the equations as < or ≥1.8 mmol/L (70 mg/dL) that were correctly classified when compared with preparative ultracentrifugation in patients with triglyceride levels of 1.7–4.5 mmol/L (150–399 mg/dL). N’ = number of records in the double-blind treatment period with an LDL-C measurement by preparative ultracentrifugation and Friedewald, for the given category. LDL-C, low-density lipoprotein; PUC, preparative ultracentrifugation.
See this image and copyright information in PMC

References

    1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–188. - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2019;139:e1082–e143. - PMC - PubMed
    1. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet North Am Ed 2016;388:2532–2561. - PubMed
    1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel. Eur Heart J 2017;38:2459–2472. - PMC - PubMed
    1. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med 2019;381:1557–1567. - PubMed

Publication types

Associated data